Document Detail

Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
MedLine Citation:
PMID:  14686964     Owner:  NLM     Status:  MEDLINE    
AIM: Impaired fibrinolysis is frequently observed in patients with the metabolic syndrome. Aim of the study was to examine the short-term effect of angiotensin II receptor blockade on the fibrinolytic system.
METHODS: Seventy-four patients with mild hypertension were randomly assigned to a 7-day treatment period with either 16 mg candesartan cilexetil or placebo. Several variables of the fibrinolytic system such as plasminogen activator inhibitor-1 (PAI-1) antigen and activity, tissue plasminogen activator (t-PA) antigen and activity as well as circulating t-PA/PAI-1 complexes were determined.
RESULTS: At baseline, the body mass index but not blood pressure was positively associated with PAI-1 antigen (r=0.314, p<0.01) and PAI-1 activity (r=0.425, p<0.01) but negatively with t-PA activity (r=-0.187, p < 0.05). A 7-day treatment with 16 mg candesartan cilexetil resulted in a significant greater reduction of diastolic blood pressure (-10.3 +/- 10.8 mmHg vs.-5.8 +/- 8.5 mmHg, p=0.03). However, there was no significant effect of candesartan on all parameters of the fibrinolytic system under investigation, i.e. circulating PAI-1 antigen, PAI-1 activity, t-PA antigen, t-PA activity and t-PA/PAI-1 complexes. Furthermore, candesartan did not affect the characteristic circadian pattern of the variables of the fibrinolytic system.
CONCLUSION: We conclude that short-term blockade of the angiotensin II receptor subtype 1 with candesartan does not have an impact on fibrinolysis in patients with mild hypertension.
T Skurk; Y-M Lee; T-O Nicuta-Rölfs; B Haastert; A Wirth; H Hauner
Related Documents :
6326614 - Actions of angiotensin ii on the brain: mechanisms and physiologic role.
16783414 - The role of urotensin ii in cardiovascular and renal physiology and diseases.
24621044 - Validity and reliability of a pressure ulcer monitoring tool for persons with spinal co...
20739604 - Drinking and arterial blood pressure responses to ang ii in young and old rats.
20536154 - Bicellar mixture phase behavior examined by variable-pressure deuterium nmr and ambient...
8154024 - Enhancement of the recovery of rat hearts after prolonged cold storage by cyclocreatine...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  6     ISSN:  1462-8902     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2003-12-22     Completed Date:  2004-05-24     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  56-62     Citation Subset:  IM    
German Diabetes Research Institute at the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin Receptor Antagonists*
Antihypertensive Agents / pharmacology*
Benzimidazoles / pharmacology*
Biphenyl Compounds / pharmacology*
Circadian Rhythm / drug effects
Double-Blind Method
Fibrinolysis / drug effects*
Hypertension / blood*,  drug therapy
Middle Aged
Plasminogen Activator Inhibitor 1 / blood
Tissue Plasminogen Activator / blood
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Plasminogen Activator Inhibitor 1; 0/Tetrazoles; EC Plasminogen Activator; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
Next Document:  The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tole...